Lixisenatide attenuates advanced glycation end products (AGEs)-induced degradation of extracellular matrix in human primary chondrocytes
Source abstract
Abstract
Osteoarthritis (OA) poses a growing threat to the health of the global population. Accumulation of advanced glycation end-products (AGEs) has been shown to upregulate expression of degradative enzymes such as matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) in chondrocytes, which leads to excessive degradation of type II collagen and aggrecan in the articular extracellular matrix (ECM). In the present study we investigated the effects of the GLP-1 agonist lixisenatide, a widely used type II diabetes medication, on AGEs-induced decreased mitochondrial membrane potential (MMP), degradation of ECM, oxidative stress, expression of cytokines including interleukin (IL)-1β and IL-6, and activation of nuclear factor kappa B (NF-κB). Our findings indicate that lixisenatide significantly ameliorated the deleterious effects of AGEs in a dose-dependent manner. Thus, lixisenatide has potential as a safe and effective treatment for OA and other AGEs-induced inflammatory diseases.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Glycation End Products research · Osteoarthritis Treatment and Mechanisms · Peroxisome Proliferator-Activated Receptors
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Orthopaedics, The Second Hospital of Jilin University
Funding
Science and Technology Development Project of Jilin Province · Health Special Project of Jilin Province
References (33)
Show source-provided references
1. 10.1136/annrheumdis-2013-20476310.1136/annrheumdis-2013-204763 ↗
2. 10.3892/mmr.2016.552310.3892/mmr.2016.5523 ↗
3. 10.22203/eCM.v021a1610.22203/eCM.v021a16 ↗
4. 10.3390/biom501019410.3390/biom5010194 ↗
5. 10.1016/j.redox.2013.12.01610.1016/j.redox.2013.12.016 ↗
6. 10.1074/jbc.M112.34897910.1074/jbc.M112.348979 ↗
7. 10.1073/pnas.120499110910.1073/pnas.1204991109 ↗
8. 10.1016/S0070-2153(06)79005-610.1016/S0070-2153(06)79005-6 ↗
9. 10.1074/jbc.R113.45121110.1074/jbc.R113.451211 ↗
10. 10.1016/B978-0-12-809847-9.00002-710.1016/B978-0-12-809847-9.00002-7 ↗
11. 10.1002/art.3909910.1002/art.39099 ↗
12. 10.1016/j.joca.2015.02.90210.1016/j.joca.2015.02.902 ↗
13. 10.1002/jcb.2329810.1002/jcb.23298 ↗
14. 10.1016/j.joca.2010.08.01610.1016/j.joca.2010.08.016 ↗
15. 10.1097/01.ASN.0000077413.41276.1710.1097/01.ASN.0000077413.41276.17 ↗
16. 10.1016/j.joca.2006.04.00810.1016/j.joca.2006.04.008 ↗
17. 10.1056/NEJMoa150922510.1056/NEJMoa1509225 ↗
18. 10.1016/j.neuropharm.2014.07.01510.1016/j.neuropharm.2014.07.015 ↗
19. 10.1007/s00125-017-4330-310.1007/s00125-017-4330-3 ↗
20. 10.1155/2016/309464210.1155/2016/3094642 ↗
21. 10.1111/bcpt.1285010.1111/bcpt.12850 ↗
22. 10.1053/j.gastro.2007.03.05410.1053/j.gastro.2007.03.054 ↗
23. Berenbaum F Bougault C Attali C inventors Assistance Publique Hopitaux de Paris assignee. Treatment of osteoarthritis with incretin hormones or analogues thereof. U.S. Patent No. 9 592 272. 2017 March 14.
24. FDA. Sanofi new drug application for lixisenatide accepted for review by FDA; 2013 Feb 19; Available from: Drugs.com/PRNewsire.
25. 10.1016/j.celrep.2018.04.10510.1016/j.celrep.2018.04.105 ↗
26. Smith MD, Triantafillou S, Parker A, et al. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol. 1997;24:365–371.
27. Fernandes JC, Martel‐Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002;39:237–246.
28. 10.1016/j.ajpath.2016.06.01010.1016/j.ajpath.2016.06.010 ↗
29. 10.1042/bj2003040710.1042/bj20030407 ↗
30. 10.1007/s12272-011-0113-410.1007/s12272-011-0113-4 ↗
31. 10.1016/j.biopha.2018.04.01810.1016/j.biopha.2018.04.018 ↗
32. 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-410.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4 ↗
33. 10.1016/S0092-8674(00)80406-710.1016/S0092-8674(00)80406-7 ↗